Product Datasheet

Anti-HRSV Fusion Protein Reference Antibody (Suptavumab, RUO)
Catalog No.: BS10515

Product Information

Catalog No.	BS10515
Product name	Anti-HRSV Fusion Protein Reference Antibody (Suptavumab, RUO)
Applications	ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Species reactivity	HRSV-A
Host species	Human
Clonality	Monoclonal
Isotype	IgG1, kappa
Form	Liquid
Storage buffer	0.01M PBS, pH 7.4.
Concentration	1.64mg/ml
Purity	>95% purity as determined by SDS-PAGE.
Purification	Protein A/G purified from cell culture supernatant.
Target	F, Fusion glycoprotein F0, Fusion glycoprotein F2, p27, Intervening segment, Pep27, Peptide 27, Fusion glycoprotein F1
Expression system	Mammalian Cells
Accession	P03420
Endotoxin level	Please contact the lab for this information.
Stability and Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.
Alternative Names	H1H3592P3, REGN2222, SAR-438584, SAR438584, REGN2222, 1629615-23-1
Note	For research use only. Not suitable for clinical or therapeutic use.

Background

Palivizumab (brand name Synagis) is a humanized IgG monoclonal antibody (mAb) manufactured by MedImmune with recombinant DNA technology. It is used in the prevention of respiratory syncytial virus (RSV) infections. It is recommended for infants that are high-risk because of prematurity or other medical problems such as congenital heart disease. Palivizumab directed against an epitope in the A antigenic site of the F protein of RSV. Palivizumab is a composite of human (95%) and murine (5%) antibody sequences. The human heavy chain sequence was derived from the constant domains of human IgG1 and the variable framework regions of the VH genes Cor and Cess. The human light chain sequence was derived from the constant domain of Cκ and the variable framework regions of the VL gene K104 with Jκ -4. The murine sequences were derived from a murine monoclonal antibody, Mab 1129, in a process that involved the grafting of the murine complementarity determining regions into the human antibody frameworks. Palivizumab is composed of two heavy chains and two light chains and has a molecular weight of approximately 148, 000 Daltons. Palivizumab was approved for medical use in 1998 but the indications for prophylaxis vary worldwide. Palivizumab is primarily indicated for the following conditions: prematurity (gestational age ≤ 35 weeks), bronchopulmonary dysplasia/chronic lung disease, hemodynamically significant congenital heart disease, and other serious medical disorders on an ad hoc basis. Infants with these medical conditions are at increased risk of more severe disease and more serious subsequent sequelae.

Image Data



SEC-HPLC

SEC-HPLC detection for Research Grade Suptavumab.



SDS-PAGE

SDS-PAGE for Research Grade Suptavumab.